RNA methylation sequencing market seen topping $1.34B by 2030

The global RNA methylation sequencing market is projected to grow from $0.77 billion in 2026 to $1.34 billion by 2030, according to The Business Research Company. Demand is rising as precision medicine, cancer research and AI-driven sequencing tools expand use cases in genomics and drug discovery.

Why it matters: - RNA methylation sequencing is becoming more important in precision medicine, cancer research and drug discovery. - The market’s projected rise signals broader adoption of epitranscriptomic profiling across academic, pharmaceutical and clinical research. - The report points to a fast-growing segment in biomedical tools as researchers seek better ways to detect RNA modifications linked to disease.

What happened: - The Business Research Company released its Ribonucleic Acid (RNA) Methylation Sequencing Global Market Report 2026. - The report projects the market will grow from $0.66 billion in 2025 to $0.77 billion in 2026. - The market is forecast to reach $1.34 billion by 2030. - The report places the 2026-2030 compound annual growth rate at 15.0%. - The company published a free sample of the report and the full market report online: More information and the full report.

The details: - RNA methylation sequencing detects, maps and quantifies chemical modifications on RNA, including N6-methyladenosine, or m6A. - The method uses sequencing platforms, chemical enrichment and bioinformatics tools to produce high-resolution maps of RNA modification patterns. - The report says historical growth was driven by more epigenetics and transcriptomics funding, better next-generation sequencing platforms, stronger interest in cancer genomics and biomarker discovery, wider use of methylation-sensitive immunoprecipitation methods, and more RNA biology research in academia and pharma. - Looking ahead, the report highlights AI tools for methylation detection, single-molecule and long-read sequencing, cloud-based multi-omics integration and direct RNA nanopore sequencing as key growth drivers. - The report also flags m6A immunoprecipitation sequencing, AI-driven bioinformatics pipelines and high-throughput transcriptome-wide methylation mapping as major trends. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - Precision medicine is pushing demand because RNA methylation data can help identify disease-specific signatures and improve patient stratification. - Cancer remains a major use case because RNA modification patterns can help with biomarker discovery, early detection, prognosis and treatment targeting. - The market outlook also reflects wider spending on research and development, especially in pharmaceutical and biomedical innovation. - The report cites rising global cancer incidence as a key backdrop, including a World Health Organization projection of more than 35 million new cases by 2050, up 77% from about 20 million in 2022. - The report cites UK business R&D spending of $64.73 billion in 2023, up 2.9% from 2022, as another sign of stronger research investment.

What's next: - The market’s next phase will likely center on AI-assisted analysis, cloud analytics and higher-throughput sequencing workflows. - Growth may accelerate as more drug developers and research groups use RNA methylation data to support therapeutic targeting and multi-omics studies. - The company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, forecasting dashboards and trend analysis.

The bottom line: - RNA methylation sequencing is moving from a niche research tool toward a broader genomics platform, with strong demand expected through 2030.